ClinicalTrials.gg
RecruitingNCT07540754Updated Jun 1, 2026

A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

A Phase 1 interventional study of HRS9531 Injection in Diabetes Mellitus and Weight Loss, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd. — 4 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
8th of 13
24 · median 30
Started
2026
with 1 other
Phase 1
13 of 13
4 open now
Registered
13th of 13
by date

Among the 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd., this one is the 8th largest by planned enrollment, is one of 2 that started in 2026, is one of 13 in phase 1, and was the 13th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

4 of the 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild/moderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531 Injection in these participants.

03

Conditions studied

  • Diabetes Mellitus
  • Weight Loss
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must fully understand and voluntarily sign a written form before the trial, demonstrating comprehension of the trial content, procedures, and potential adverse reactions; they must also be willing and able to comply with the protocol requirements to complete the study.
  2. Female participants of must have a negative baseline serum pregnancy test, must not be lactating, and must agree to use measures and refrain from egg donation from the time of signing the informed consent form until 2 months after the last dose of the study drug; male participants with partners of childbearing potential must agree to use contraceptive measures and refrain from sperm donation from the time of signing the informed consent form until 2 months after the last dose of the study drug.
  3. Aged 18 to 65 years (inclusive), both male and female.
  4. Male participants weigh no less than 50 kg, and female participants weigh no less than 45 kg. (BMI) is within the range of 19.0 to 40.0 kg/m² (inclusive).

Exclusion criteria

Exclusion Criteria:

  1. Participation in any clinical trial of a drug or medical device within 3 months prior to dosing, or currently within the follow-up period of a clinical study or within 5 half-lives of the drug (whichever is longer).
  2. Allergic constitution, including a history of severe drug allergy or drug anaphylaxis, excluding untreated asymptomatic seasonal allergies or individuals with positive skin tests only.
  3. Smokers and drinkers who are unable to abstain during the trial period; positive alcohol screening test.
  4. Drug abusers or those with a positive urine drug screening test.
  5. Blood loss or blood donation ≥400 mL within 3 months prior to dosing, or blood loss or blood donation ≥ 200 mL within 1 month prior to dosing, or receipt of a blood transfusion within 3 months prior to dosing.
  6. Undergone any surgery within 6 months prior to dosing, or planned to undergo surgical procedures during the study period.
  7. Suffering from malignant tumors, or having a history of malignant tumors within 5 years prior to screening (excluding non-melanoma skin cancer that has been treated with no signs of recurrence, and resected cervical intraepithelial neoplasia).
  8. History of severe hypoglycemia.
  9. Previous significant gastric emptying abnormalities or factors affecting gastric emptying (e.g., history of gastric bypass surgery, pyloric stenosis), or severe gastrointestinal diseases (e.g., active peptic ulcer, inflammatory bowel disease, etc.), or have undergone gastrointestinal surgery (excluding surgeries with no significant impact on gastrointestinal motility, such as removal of gastrointestinal polyps, appendectomy, hemorrhoidectomy, etc.).
  10. Anyone with factors making them unsuitable to participate in this trial evaluated by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Group of Participants with mild hepatic impairment

    Participants with mild hepatic impairment.

    Drug: HRS9531 Injection

  • Experimental
    Group of Participants with moderate hepatic impairment

    Participants with moderate hepatic impairment.

    Drug: HRS9531 Injection

  • Experimental
    Group of Participants with normal hepatic function

    Participants with normal hepatic function.

    Drug: HRS9531 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax)

    HRS9531 key PK parameter.

    Time frame: Post-dose from Day 1 to Day 29.

  2. The area under the concentration-time curve to the last measurable concentration (AUClast)

    HRS9531 key PK parameter.

    Time frame: Post-dose from Day 1 to Day 29.

  3. The area under the concentration-time curve extrapolated to infinity (AUCinf)

    HRS9531 key PK parameter.

    Time frame: Post-dose from Day 1 to Day 29.

Secondary outcomes

  1. Time to maximum concentration (Tmax)

    HRS9531 other PK parameter.

    Time frame: Post-dose from Day 1 to Day 29.

  2. Half-life (t1/2)

    HRS9531 other PK parameter.

    Time frame: Post-dose from Day 1 to Day 29.

  3. Apparent clearance (CL/F)

    HRS9531 other PK parameter.

    Time frame: Post-dose from Day 1 to Day 29.

  4. Apparent volume of distribution (Vz/F)

    HRS9531 other PK parameter.

    Time frame: Post-dose from Day 1 to Day 29.

  5. Adverse events (AEs)

    Safety and tolerability measure.

    Time frame: Day 1 to Day 36.

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Recruiting
    • Zujiang Yu · Contactjohnyuem@zzu.edu.cn · +86-0371-6691694
    • Xin Tian · Contacttianx@zzu.cn · +86-13903830361
    • Zujiang Yu · Principal investigator
    • Xin Tian · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2027, 8 months after the start.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 8 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 20, 2026
StartActual
May 26, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Feb 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07540754
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
May 26, 2026
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Yanyan Zhang
Contact
yanyan.zhang@hengrui.com
+86-0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion